-
Je něco špatně v tomto záznamu ?
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
P. Pozo-Rosich, HC. Detke, S. Wang, D. Doležil, LQ. Li, SK. Aurora, U. Reuter
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- humanizované monoklonální protilátky škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- migréna * farmakoterapie prevence a kontrola MeSH
- mladiství MeSH
- mladý dospělý MeSH
- monoklonální protilátky terapeutické užití MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study. Long-term safety and efficacy were assessed in an open-label extension. METHODS: Patients 18-65 years old with chronic migraine completing the 3-month double-blind period of REGAIN could enter a 9-month open-label extension (OLE; months 4-12). Upon entering the OLE, patients received a 240-mg galcanezumab loading dose, then 120 mg at the next month, with flexible dosing thereafter (120 or 240 mg/month). The primary efficacy measure was the mean change in the number of monthly migraine headache days from double-blind baseline to month 12. Other endpoints included response rates (based on percent reduction in monthly migraine headache days from double-blind baseline to month 12), safety and tolerability. RESULTS: Of patients who completed double-blind treatment, 1022 (99%) entered the OLE, with 81% completing month 12. From a baseline of 19.4 monthly migraine headache days at the beginning of the double-blind period, patients at month 12 in the previous placebo, 120-mg, and 240-mg galcanezumab groups had a mean change of -8.5, -9.0, and -8.0, respectively (SE = 0.43 to 0.55, within-group p's < .001). At month 12, the percentage of patients with ≥50% response was 57%, 57%, and 53%, respectively. Percentage with ≥75% response was 32%, 31%, and 30%, respectively. Percentage with 100% response was 8%, 6%, and 6%, respectively. There were no significant new safety findings during the open-label period. The incidence of discontinuation from the OLE due to adverse events was 5%. CONCLUSION: Galcanezumab was effective, safe, and well-tolerated, with high adherence, for up to 12 months of treatment in patients with chronic migraine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02614261; www.clinicaltrials.gov/ct2/show/NCT02614261.
Department of Neurology Charité Universitätsmedizin Berlin Berlin Germany
Eli Lilly and Company Indianapolis IN USA
Headache Unit Neurology Department Vall d'Hebron University Hospital Barcelona Spain
Now at Impel NeuroPharma Seattle WA USA
Now at Sarepta Therapeutics Cambridge MA USA
Prague Headache Center DADO MEDICAL s r o Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018536
- 003
- CZ-PrNML
- 005
- 20220804134837.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/03007995.2022.2059975 $2 doi
- 035 __
- $a (PubMed)35392739
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pozo-Rosich, Patricia $u Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain $u Headache and Neurological Pain Research Group, Vall d'Hebron Institute of Research (VHIR), Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
- 245 10
- $a Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study / $c P. Pozo-Rosich, HC. Detke, S. Wang, D. Doležil, LQ. Li, SK. Aurora, U. Reuter
- 520 9_
- $a BACKGROUND: Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study. Long-term safety and efficacy were assessed in an open-label extension. METHODS: Patients 18-65 years old with chronic migraine completing the 3-month double-blind period of REGAIN could enter a 9-month open-label extension (OLE; months 4-12). Upon entering the OLE, patients received a 240-mg galcanezumab loading dose, then 120 mg at the next month, with flexible dosing thereafter (120 or 240 mg/month). The primary efficacy measure was the mean change in the number of monthly migraine headache days from double-blind baseline to month 12. Other endpoints included response rates (based on percent reduction in monthly migraine headache days from double-blind baseline to month 12), safety and tolerability. RESULTS: Of patients who completed double-blind treatment, 1022 (99%) entered the OLE, with 81% completing month 12. From a baseline of 19.4 monthly migraine headache days at the beginning of the double-blind period, patients at month 12 in the previous placebo, 120-mg, and 240-mg galcanezumab groups had a mean change of -8.5, -9.0, and -8.0, respectively (SE = 0.43 to 0.55, within-group p's < .001). At month 12, the percentage of patients with ≥50% response was 57%, 57%, and 53%, respectively. Percentage with ≥75% response was 32%, 31%, and 30%, respectively. Percentage with 100% response was 8%, 6%, and 6%, respectively. There were no significant new safety findings during the open-label period. The incidence of discontinuation from the OLE due to adverse events was 5%. CONCLUSION: Galcanezumab was effective, safe, and well-tolerated, with high adherence, for up to 12 months of treatment in patients with chronic migraine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02614261; www.clinicaltrials.gov/ct2/show/NCT02614261.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a humanizované monoklonální protilátky $x škodlivé účinky $7 D061067
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a migréna $x farmakoterapie $x prevence a kontrola $7 D008881
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Detke, Holland C $u Eli Lilly and Company, Indianapolis, IN, USA $1 https://orcid.org/0000000213166064
- 700 1_
- $a Wang, Shufang $u Eli Lilly and Company, Indianapolis, IN, USA $u Now at Sarepta Therapeutics, Cambridge, MA, USA
- 700 1_
- $a Doležil, David $u Prague Headache Center, DADO MEDICAL s.r.o, Prague, Czech Republic
- 700 1_
- $a Li, Lily Q $u Eli Lilly and Company, Indianapolis, IN, USA
- 700 1_
- $a Aurora, Sheena K $u Eli Lilly and Company, Indianapolis, IN, USA $u Now at Impel NeuroPharma, Seattle, WA, USA
- 700 1_
- $a Reuter, Uwe $u Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 773 0_
- $w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 38, č. 5 (2022), s. 731-742
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35392739 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134830 $b ABA008
- 999 __
- $a ok $b bmc $g 1822231 $s 1169779
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 38 $c 5 $d 731-742 $e 20220415 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
- LZP __
- $a Pubmed-20220720